Global Blood: Q1 Earnings Snapshot
May 5, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (AP) Global Blood Therapeutics Inc. (GBT) on Wednesday reported a loss of $74.9 million in its first quarter.
The South San Francisco, California-based company said it had a loss of $1.21 per share.
The results did not meet Wall Street expectations. The average estimate of 14 analysts surveyed by Zacks Investment Research was for a loss of $1.02 per share.
The biopharmaceutical company posted revenue of $39 million in the period, which also did not meet Street forecasts. Eleven analysts surveyed by Zacks expected $42.9 million.
Global Blood shares have decreased 8% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $39.83, a fall of 50% in the last 12 months.
Published: May 04, 2021
SAN DIEGO (BUSINESS WIRE) Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.
“Christine has an impressive track record of leading both private and public biotechnology companies through critical value-creating inflection points, and we are excited to welcome her to our board of directors,” said Jeffrey Hatfield, chief executive officer of Vividion. “As Vividion continues to make progress building a company and pipeline aimed at delivering precision therapeutics for cancer and immune disorders, we look forward to leveraging her wealth of experience and unique per
Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open)
Endo International plc (NASDAQ: ENDP) (before the market open)
Bio-Techne Corporation (NASDAQ: TECH) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
Athenex, Inc. (NASDAQ: ATNX) (before the market open)
Zoetis Inc. (NYSE: ZTS) (before the market open)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open)
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (before the market open)
Sickle Cell Disease Drug Market Report Coverage:
Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast.
Latest launched research on Global
Sickle Cell Disease Drug Market, it provides detailed analysis with presentable graphs, charts and tables. This report covers an in depth study of the Sickle Cell Disease Drug Market size, growth, and share, trends, consumption, segments, application and Forecast 2027. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Sickle Cell Disease Drug Market. This report has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the global Sickle Cell Disease Drug Market. Buyers of the report will have access to accurate